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Summary 
Background In an era of shifting global agendas and expanded emphasis on non-communicable diseases and injuries 
along with communicable diseases, sound evidence on trends by cause at the national level is essential. The Global 
Burden of Diseases, Injuries, and Risk Factors Study (GBD) provides a systematic scientific assessment of published, 
publicly available, and contributed data on incidence, prevalence, and mortality for a mutually exclusive and 
collectively exhaustive list of diseases and injuries. 
Methods GBD estimates incidence, prevalence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and
disability-adjusted life-years (DALYs) due to 369 diseases and injuries, for two sexes, and for 204 countries and territories.
Input data were extracted from censuses, household surveys, civil registration and vital statistics, disease registries,
health service use, air pollution monitors, satellite imaging, disease notifications, and other sources. Cause-specific
death rates and cause fractions were calculated using the Cause of Death Ensemble model and spatiotemporal Gaussian
process regression. Cause-specific deaths were adjusted to match the total all-cause deaths calculated as part of the GBD
population, fertility, and mortality estimates. Deaths were multiplied by standard life expectancy at each age to calculate
YLLs. A Bayesian meta-regression modelling tool, DisMod-MR 2.1, was used to ensure consistency between incidence,
prevalence, remission, excess mortality, and cause-specific mortality for most causes. Prevalence estimates were
multiplied by disability weights for mutually exclusive sequelae of diseases and injuries to calculate YLDs. We considered
results in the context of the Socio-demographic Index (SDI), a composite indicator of income per capita, years of
schooling, and fertility rate in females younger than 25 years. Uncertainty intervals (UIs) were generated for every
metric using the 25th and 975th ordered 1000 draw values of the posterior distribution. 
Findings Global health has steadily improved over the past 30 years as measured by age-standardised DALY rates. After
taking into account population growth and ageing, the absolute number of DALYs has remained stable. Since 2010, the
pace of decline in global age-standardised DALY rates has accelerated in age groups younger than 50 years compared
with the 1990–2010 time period, with the greatest annualised rate of decline occurring in the 0–9-year age group.
Six infectious diseases were among the top ten causes of DALYs in children younger than 10 years in 2019: lower
respiratory infections (ranked second), diarrhoeal diseases (third), malaria (fifth), meningitis (sixth), whooping cough
(ninth), and sexually transmitted infections (which, in this age group, is fully accounted for by congenital syphilis; ranked
tenth). In adolescents aged 10–24 years, three injury causes were among the top causes of DALYs: road injuries (ranked
first), self-harm (third), and interpersonal violence (fifth). Five of the causes that were in the top ten for ages 10–24 years
were also in the top ten in the 25–49-year age group: road injuries (ranked first), HIV/AIDS (second), low back pain
(fourth), headache disorders (fifth), and depressive disorders (sixth). In 2019, ischaemic heart disease and stroke were the
top-ranked causes of DALYs in both the 50–74-year and 75-years-and-older age groups. Since 1990, there has been a
marked shift towards a greater proportion of burden due to YLDs from non-communicable diseases and injuries.
In 2019, there were 11 countries where non-communicable disease and injury YLDs constituted more than half of all
disease burden. Decreases in age-standardised DALY rates have accelerated over the past decade in countries at the lower
end of the SDI range, while improvements have started to stagnate or even reverse in countries with higher SDI. 
Interpretation As disability becomes an increasingly large component of disease burden and a larger component of
health expenditure, greater research and development investment is needed to identify new, more effective
intervention strategies. With a rapidly ageing global population, the demands on health services to deal with
disabling outcomes, which increase with age, will require policy makers to anticipate these changes. The mix of
universal and more geographically specific influences on health reinforces the need for regular reporting on
population health in detail and by underlying cause to help decision makers to identify success stories of disease
control to emulate, as well as opportunities to improve. 
Funding Bill & Melinda Gates Foundation. 
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. 
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Research in context 
Evidence before this study 
The Global Burden of Diseases, Injuries, and Risk Factors Study 
(GBD) 2017 reported on incidence, prevalence, and mortality 
from 359 diseases and injuries. Information on prevalence and 
mortality was also analysed in terms of summary measures: 
years of life lost (YLLs), years lived with disability (YLDs), 
disability-adjusted life-years (DALYs), and healthy life 
expectancy. GBD is the only comprehensive assessment 
providing time trends for a mutually exclusive and collectively 
exhaustive list of diseases and injuries. For the first time, 
GBD 2017 also produced internally consistent estimates of 
population, fertility, mortality, and migration by age, sex, 
and year for 1950–2017. GBD 2017 also included subnational 
assessments for 16 countries at administrative level 1 and for 
local authorities in England. 
Added value of this study 
GBD 2019 updates and expands beyond GBD 2017 in ten ways. 
(1) The number of countries for which subnational assessments 
have been undertaken was expanded to include Italy, Nigeria, 
Pakistan, the Philippines, and Poland. (2) 12 new causes were 
added to the GBD modelling framework, including pulmonary 
arterial hypertension, nine new sites of cancer, and two new 
sites of osteoarthritis (hand and other joints). (3) For each 
disease, the preferred or reference case definition or 
measurement method was clearly defined and stored in a 
database. For both risks and diseases, the statistical relationship 
between the alternative and reference measurement method 
was analysed using network meta-regression using only data 
where two different approaches were measured in the same 
location–time period. Although statistical cross-walking 
between alternative and reference definitions and 
measurement methods has been a feature in all GBD studies, 
the approach in GBD 2019 was highly standardised and used 
improved methods across diseases and risks. (4) Some prior 
Introduction 
The Global Burden of Diseases, Injuries, and Risk Factors
Study (GBD) provides a systematic scientific assessment
of published, publicly available, and contributed data on
disease and injury incidence, prevalence, and mortality
for a mutually exclusive and collectively exhaustive list
of diseases and injuries.1–3 In an era of shifting global
agendas and expanded emphasis on non-communicable
diseases and injuries along with communicable diseases,
sound and up-to-date evidence on trends—both progress
and adverse patterns—by cause at the national level is
essential to reflect effects of public health policy and
medical care delivery.4–7 
GBD 2019 provides an opportunity to incorporate 
newly available datasets, enhance method performance 
and standardisation, and reflect changes in scientific 
understanding. Since GBD 2017,1–3 no comprehensive 
update of descriptive epidemiology levels and trends has 
distributions used in DisMod-MR, the Bayesian meta-regression 
tool used to simultaneously estimate incidence, prevalence, 
remission, excess mortality, and cause-specific mortality, 
were revised on the basis of simulation studies showing that 
less informative priors helped to improve the coverage of 
uncertainty intervals. (5) Redistribution algorithms for sepsis, 
heart failure, pulmonary embolism, acute kidney injury, hepatic 
failure, acute respiratory failure, pneumonitis, and five 
intermediate causes in the central nervous system were revised 
according to an analysis of 116 million deaths that were 
attributed to multiple causes. (6) Processing of clinical 
informatics data on hospital and clinic visits was revised to 
better take into account differential access across locations to 
health-care facilities. (7) To enhance the stability of models in 
the presence of the addition of subnational data in different 
GBD cycles, we adopted a set of standard locations for the 
estimation of covariate effects in models. (8) 7333 national and 
24 657 subnational vital registration systems, 16 984 published 
studies, and 1654 household surveys were used in the analysis, 
including many newly available data sources. (9) Results are 
presented so as to integrate causes of death, incidence, 
prevalence, YLDs, YLLs, and DALYs into a comprehensive 
assessment of each disease and injury. (10) Closer technical 
coordination with WHO has led to the addition of nine WHO 
member states to the analysis and revisions of the analytical 
approach for select diseases. 
Implications of all the available evidence 
GBD 2019 provides the most up-to-date assessment of the
descriptive epidemiology of a mutually exclusive and collectively
exhaustive list of diseases and injuries for 204 countries and
territories from 1990 to 2019. The comprehensive nature of the
assessment provides policy-relevant information on the trends
of major causes of burden globally, regionally, and by country or
territory. 
been released, to our knowledge. In this study, we 
summarise GBD methods and present integrated results 
on fatal and non-fatal outcomes for the GBD disease 
and injury hierarchical cause list. GBD 2019 includes 
estimation of numerous different models for disease and 
injury outcomes. This Article provides a high-level over­
view of our findings. Results are presented both broadly 
and in detail for a selection of diseases, injuries, and 
impairments in two-page summaries with a standard set 
of tables and figures. 
Methods 
Overview 
The general approach to estimating causes of death and 
disease incidence and prevalence for GBD 2019 is the 
same as for GBD 2017.2,3 Appendix 1 provides details on 
the methods used to model each disease and injury. 
Here, we provide an overview of the methods, with an 
See Online for appendix 1 
www.thelancet.com Vol 396   October 17, 2020 1205 
Global Health Metrics
    
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
For the statistical code see 
http://ghdx.healthdata.org/gbd­
2019/code 
For the GHDx see http://ghdx. 
healthdata.org 
For the GHDx source tool see 
http://ghdx.healthdata.org/gbd­
2019/data-input-sources 
See Online for appendix 2 
emphasis on the main methodology changes since 
GBD 2017. 
For each iteration of GBD, the estimates for the whole 
time series are updated on the basis of addition of new 
data and change in methods where appropriate. Thus, 
the GBD 2019 results supersede those from previous 
rounds of GBD. 
GBD 2019 complies with the Guidelines for Accurate
and Transparent Health Estimates Reporting (GATHER)
statement (appendix 1 section 1.4).8 Analyses were com­
pleted with Python version 3.6.2, Stata version 13, and
R version 3.5.0. Statistical code used for GBD estimation
is publicly available online. 
Geographical units, age groups, time periods, and cause 
levels 
GBD 2019 estimated each epidemiological quantity of
interest—incidence, prevalence, mortality, years lived
with disability (YLDs), years of life lost (YLLs), and
disability-adjusted life-years (DALYs)—for 23 age
groups; males, females, and both sexes combined; and
204 countries and territories that were grouped into
21 regions and seven super-regions. For GBD 2019,
nine countries and territories (Cook Islands, Monaco,
San Marino, Nauru, Niue, Palau, Saint Kitts and Nevis,
Tokelau, and Tuvalu) were added, such that the GBD
location hierarchy now includes all WHO member
states. GBD 2019 includes subnational analyses for
Italy, Nigeria, Pakistan, the Philippines, and Poland,
and 16 countries previously estimated at subnational
levels (Brazil, China, Ethiopia, India, Indonesia, Iran,
Japan, Kenya, Mexico, New Zealand, Norway, Russia,
South Africa, Sweden, the UK, and the USA). All
subnational analyses are at the first level of admin­
istrative organisation within each country except for
New Zealand (by Māori ethnicity), Sweden (by
Stockholm and non-Stockholm), the UK (by local gov­
ernment authorities), and the Philippines (by province).
In this publication, we present subnational estimates
for Brazil, India, Indonesia, Japan, Kenya, Mexico,
Sweden, the UK, and the USA; given space constraints,
these results are presented in appendix 2. At the most
detailed spatial resolution, we generated estimates for
990 locations. The GBD diseases and injuries analytical
framework generated estimates for every year from
1990 to 2019. 
Diseases and injuries were organised into a levelled
cause hierarchy from the three broadest causes of death
and disability at Level 1 to the most specific causes at
Level 4. Within the three Level 1 causes—communicable,
maternal, neonatal, and nutritional diseases; non-commu­
nicable diseases; and injuries—there are 22 Level 2 causes,
174 Level 3 causes, and 301 Level 4 causes (including
131 Level 3 causes that are not further disaggregated at
Level 4; see appendix 1 sections 3.4 and 4.12 for the full list
of causes). 364 total causes are non-fatal and 286 are fatal.
For GBD 2019, 12 new causes were added to the modelling
framework: pulmonary arterial hypertension, eye cancer,
soft tissue and other extraosseous sarcomas, malignant
neoplasm of bone and articular cartilage, and neuro­
blastoma and other peripheral nervous cell tumours at
Level 3, and hepatoblastoma, Burkitt lymphoma, other
non-Hodgkin lymphoma, retinoblastoma, other eye can­
cers, and two sites of osteoarthritis (hand and other joints)
at Level 4. 
Data 
The GBD estimation process is based on identifying
multiple relevant data sources for each disease or injury
including censuses, household surveys, civil registration
and vital statistics, disease registries, health service use,
air pollution monitors, satellite imaging, disease notifi­
cations, and other sources. Each of these types of data are
identified from systematic review of published studies,
searches of government and international organisation
websites, published reports, primary data sources such as
the Demographic and Health Surveys, and contributions
of datasets by GBD collaborators. 86249 sources were
used in this analysis, including 19354 sources reporting
deaths, 31499 reporting incidence, 19773 reporting prev­
alence, and 26631 reporting other metrics. Each newly
identified and obtained data source is given a unique
identifier by a team of librarians and included in the
Global Health Data Exchange (GHDx). The GHDx makes
publicly available the metadata for each source included in
GBD as well as the data, where allowed by the data
provider. Readers can use the GHDx source tool to identify
which sources were used for estimating any disease or
injury outcome in any given location. 
Data processing 
A crucial step in the GBD analytical process is correcting
for known bias by redistributing deaths from unspecified
codes to more specific disease categories, and by adjusting
data with alternative case definitions or measurement
methods to the reference method. We highlight several
major changes in data processing that in some cases have
affected GBD results. 
Cause of death redistribution 
Vital registration with medical certification of cause of 
death is a crucial resource for the GBD cause of death 
analysis in many countries. Cause of death data obtained 
using various revisions of the International Classification 
of Diseases and Injuries (ICD)9 were mapped to the 
GBD cause list. Many deaths, however, are assigned to 
causes that cannot be the underlying cause of death 
(eg, cardiopulmonary failure) or are inadequately speci­
fied (eg, injury from undetermined intent). These deaths 
were reassigned to the most probable underlying causes 
of death as part of the data processing for GBD. 
Redistribution algorithms can be divided into three 
categories: proportionate redistribution, fixed proportion 
redistribution based on published studies or expert 
1206 www.thelancet.com Vol 396   October 17, 2020 
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judgment, or statistical algorithms. For GBD 2019, data 
for 116 million deaths attributed to multiple causes were 
analysed to produce more empirical redistribution algo­
rithms for sepsis,10 heart failure, pulmonary embolism, 
acute kidney injury, hepatic failure, acute respiratory 
failure, pneumonitis, and five intermediate causes 
(hydrocephalus, toxic encephalopathy, compression of 
brain, encephalopathy, and cerebral oedema) in the 
central nervous system. To redistribute unspecified 
injuries, we used a method similar to that of intermediate 
cause redistribution, using the pattern of the nature of 
injury codes in the causal chain where the ICD codes X59 
(“exposure to unspecified factor”) and Y34 (“unspecified 
event, undetermined intent”) and GBD injury causes 
were the underlying cause of death. These new 
algorithms led to important changes in the causes to 
which these intermediate outcomes were redistributed. 
Additionally, data on deaths from diabetes and stroke 
lack the detail on subtype in many countries; we ran 
regressions on vital registration data with at least 50% 
of deaths coded specifically to type 1 or 2 diabetes and 
ischaemic, haemorrhagic, or subarachnoid stroke to 
predict deaths by these subtypes when these were coded 
to unspecified diabetes or stroke. 
Correcting for non-reference case definitions or measurement 
methods 
In previous cycles of GBD, data reported using alternative
case definitions or measurement methods were corrected
to the reference definition or measurement method
primarily as part of the Bayesian meta-regression models.
For example, in DisMod-MR, the population data were
simultaneously modelled as a function of country covar­
iates for variation in true rates and as a function of
indicator variables capturing alternative measurement
methods. To enhance transparency and to standardise
and improve methods in GBD 2019, we estimated
correction factors for alternative case definitions or
measurement methods using network meta-regression,
including only data where two methods were assessed in
the same location–time period or in the exact same
population. This included validation studies where two
methods had been compared in populations that were
not necessarily random samples of the general popu­
lation. Details on the correction factors from alternative
to reference measurement methods are provided in
appendix 1 (section 4.4.2). 
Clinical informatics 
Clinical informatics data include inpatient admissions,
outpatient (including general practitioner) visits, and
health insurance claims. Several data processing steps
were undertaken. Inpatient hospital data with a single
diagnosis only were adjusted to account for non-
primary diagnoses as well as outpatient care. For each
GBD cause that used clinical data, ratios of non-primary
to primary diagnosis rates were extracted from claims
in the USA, Taiwan (province of China), New Zealand,
and the Philippines, as well as USA Healthcare Cost and
Utilization Project inpatient data. Ratios of outpatient to
inpatient care for each cause were extracted from claims
data from the USA and Taiwan (province of China).
The log of the ratios for each cause were modelled by
age and sex using MR-BRT (Meta-Regression-Bayesian
Regularised Trimmed), the Bayesian meta-regression
tool. To account for the incomplete health-care access in
populations where not every person with a disease or
injury would be accounted for in administrative clinical
records, we transformed the adjusted admission rates
using a scalar derived from the Healthcare Access and
Quality Index.11 We used this approach to produce
adjusted, standardised clinical data inputs. More details
are provided in appendix 1 (section 4.3). 
Modelling 
For most diseases and injuries, processed data are
modelled using standardised tools to generate estimates
of each quantity of interest by age, sex, location, and year.
There are three main standardised tools: Cause of Death
Ensemble model (CODEm), spatiotemporal Gaussian
process regression (ST-GPR), and DisMod-MR. Previous
publications2,3,12 and the appendix provide more details on
these general GBD methods. Briefly, CODEm is a highly
systematised tool to analyse cause of death data using an
ensemble of different modelling methods for rates or
cause fractions with varying choices of covariates that
perform best with out-of-sample predictive validity
testing. DisMod-MR is a Bayesian meta-regression tool
that allows evaluation of all available data on incidence,
prevalence, remission, and mortality for a disease,
enforcing consistency between epidemiological para­
meters. ST-GPR is a set of regression methods that
borrow strength between locations and over time for
single metrics of interest, such as risk factor exposure or
mortality rates. In addition, for select diseases, particularly
for rarer outcomes, alternative modelling strategies
have been developed, which are described in appendix 1
(section 3.2). 
In GBD 2019, we designated a set of standard locations
that included all countries and territories as well as
the subnational locations for Brazil, China, India, and
the USA. Coefficients of covariates in the three main
modelling tools were estimated for these standard
locations only—ie, we ignored data from subnational
locations other than for Brazil, China, India, and the USA
(appendix 1 section 1.1). Using this set of standard
locations will prevent changes in regression coefficients
from one GBD cycle to the next that are solely due to the
addition of new subnational units in the analysis that
might have lower quality data or small populations
(appendix 1 section 1.1). Changes to CODEm for GBD 2019
included the addition of count models to the model
ensemble for rarer causes. We also modified DisMod-MR
priors to effectively increase the out-of-sample coverage of
www.thelancet.com Vol 396   October 17, 2020 1207 
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uncertainty intervals (UIs) as assessed in simulation
testing (appendix 1 section 4.5). 
For the cause Alzheimer’s disease and other dementias, 
we changed the method of addressing large variations 
between locations and over time in the assignment of 
dementia as the underlying cause of death. Based on 
a systematic review of published cohort studies, we 
estimated the relative risk of death in individuals with 
dementia. We identified the proportion of excess deaths 
in patients with dementia where dementia is the under­
lying cause of death as opposed to a correlated risk factor 
(appendix 1 section 2.6.2). We changed the strategy of 
modelling deaths for acute hepatitis A, B, C, and E from 
a natural history model relying on inpatient case fatality 
rates to CODEm models after predicting type-specific 
acute hepatitis deaths from vital registration data with 
specified hepatitis type. 
DisMod-MR was used to estimate deaths from three
outcomes (dementia, Parkinson’s, and atrial fibrillation),
and to determine the proportions of deaths by underlying
aetiologies of cirrhosis, liver cancer, and chronic kidney
disease deaths. 
Socio-demographic Index, annual rate of change, and 
data presentation 
The Socio-demographic Index (SDI) is a composite
indicator of a country’s lag-distributed income per
capita, average years of schooling, and the fertility rate in
females under the age of 25 years (appendix 1 section 6).13 
For changes over time, we present annualised rates of
change as the difference in the natural log of the values
at the start and end of the time interval divided by the
number of years in the interval. We examine the
relationship between SDI and the annualised rate of
change in age-standardised DALY rates for all causes,
apart from HIV/AIDS, natural disasters, and war and
conflict, by country or territory, for the time periods
1990–2010 and 2010–19. We deliberately subtracted out
DALYs due to HIV/AIDS because their magnitude in
Figure 1: Global DALYs and age-standardised DALY rates, 1990–2019 
Shaded sections indicate 95% uncertainty intervals. DALY=disability-adjusted 
life-year. 
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some parts of the world would have obscured the trends
in all other causes; we also subtracted out DALY rates
from natural disasters and war and conflict to avoid
trends in disease burden in some countries being
dominated by these sudden and dramatic changes. As a
measure of the epidemiological transition, we present
the ratio of YLDs due to non-communicable diseases
and injuries, and due to total burden in DALYs. We
present 95% UIs for every metric based on the 25th and
975th ordered values of 1000 draws of the posterior
distribution. 
Role of the funding source 
The funders of this study had no role in study design,
data collection, data analysis, data interpretation, or the
writing of the report. The corresponding author had full
access to the data in the study and final responsibility for
the decision to submit for publication. 
Results 
Global trends 
Between 1990 and 2019, the number of global DALYs 
remained almost constant, but once the effects of 
population growth and ageing were removed by con­
verting counts to age-standardised rates, there were clear 
improvements in overall health (figure 1). Over the past 
decade, the pace of decline in global age-standardised 
DALY rates accelerated in age groups younger than 
50 years compared with the 1990–2010 time period 
(table). The annualised rate of decline was greatest in the 
0–9-year age group. In the population aged 50 years and 
older, the rate of change was slower from 2010 to 2019 
compared with the earlier time period. 
These general trends are made up of complex trends for
specific diseases and injuries. Overall trends in the number
of DALYs across the different age groups between
1990 and 2019 are driven by some key diseases and injuries
(figure 2). The ten most important drivers of increasing
burden (ie, the causes that had the largest absolute
increases in number of DALYs between 1990 and 2019)
include six causes that largely affect older adults (ischaemic
heart disease, diabetes, stroke, chronic kidney disease,
lung cancer, and age-related hearing loss), whereas the
other four causes (HIV/AIDS, other musculoskeletal
disorders, low back pain, and depressive disorders) are
common from teenage years into old age (figure 2).
Despite these ten conditions contributing the largest
number of additional DALYs over the 30-year period, only
HIV/AIDS, other musculoskeletal disorders, and diabetes
saw large increases in age-standardised DALY rates, with
an increase of 58·5% (95% UI 37·1–89·2) for HIV/AIDS,
30·7% (27·6–34·3) for other musculoskeletal disorders,
and 24·4% (18·5–29·7) for diabetes. The burden of
HIV/AIDS, however, peaked in 2004 and has dropped
substantially after the global scale-up of antiretroviral
treatment (ART). The changes in age-standardised rates
for chronic kidney disease, age-related hearing loss, and
1208 www.thelancet.com Vol 396   October 17, 2020 
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DALYs 2019 Annualised rate of change, 1990–2010 Annualised rate of change, 2010–19 
Count Age-standardised rate DALYs Age-standardised rate DALYs Age-standardised rate 
(millions) (per 100 000) 
0–9 years 531 (458 to 621) 19 125·7 (16 495·1 to 22 382·5) −2·3% (−2·5 to −2·2) −2·5% (−2·6 to −2·3) −3·7% (−4·4 to −2·9) −4·0% (−4·7 to −3·2) 
10–24 years 229 (194 to 270) 12 313·0 (10 399·9 to 14 478·3) 0·2% (0·1 to 0·2) −0·7% (−0·8 to −0·6) −1·1% (−1·4 to −0·9) −1·3% (−1·5 to −1·1) 
25–49 years 616 (533 to 709) 22 691·2 (19 613·7 to 26 116·3) 1·4% (1·4 to 1·5) −0·4% (−0·4 to −0·3) −0·0% (−0·2 to 0·1) −1·2% (−1·4 to −1·0) 
50–74 years 832 (752 to 919) 28 263·2 (25 527·6 to 31 213·4) 1·3% (1·2 to 1·3) −1·0% (−1·0 to −0·9) 2·0% (1·8 to 2·1) −0·9% (−1·1 to −0·8) 
≥75 years 329 (308 to 351) 77 320·5 (72 372·5 to 82 440·3) 2·2% (2·2 to 2·2) −0·9% (−0·9 to −0·9) 2·3% (2·3 to 2·4) −0·8% (−0·9 to −0·8) 
All ages 2540 (2290 to 2810) 32 801·7 (29 535·1 to 36 319·5) −0·0% (−0·1 to 0·0) −1·4% (−1·5 to −1·3) −0·2% (−0·4 to 0·0) −1·3% (−1·5 to −1·1) 
DALY=disability-adjusted life-year. 
Table: Global DALYs in 2019 and annualised rate of change in DALYs and age-standardised DALY rates over 1990–2010 and 2010–19, by age group and for all ages 
depressive disorders were small (figure 2). Substantial
declines in age-standardised rates were seen in ischaemic
heart disease (28·6%, 95% UI 24·2–33·3), stroke (35·2%,
30·5–40·5), and lung cancer (16·1%, 8·2–24·0). 
The ten most important contributors to declining 
burden (ie, the causes that had the largest absolute 
decreases in number of DALYs between 1990 and 2019) 
include nine that predominantly affect children (lower 
respiratory infections, diarrhoeal diseases, neonatal dis­
orders, measles, protein-energy malnutrition, congenital 
birth defects, drowning, tetanus, and malaria), as well 
as tuberculosis, which largely affects adults. All of 
these causes with declining burden also had substantial 
decreases in age-standardised DALY rates, ranging 
from 32·6% (21·2–42·1) decline for neonatal disorders 
to 90·4% (87·5–92·8) decline for measles, not just 
decreases in the absolute number of DALYs due to 
demographic changes (figure 2A). Although most of the 
ten leading Level 3 causes of DALYs were the same for 
both sexes in 2019, road injuries (ranked fourth for 
males), cirrhosis (ninth), and lung cancer (tenth) were in 
the top ten for males only, and were replaced by low back 
pain (ranked sixth for females), gynaecological diseases 
(ninth), and headache disorders (tenth) for females 
(appendix 2 figure S5 and tables S2–5, S7, S8, S12, S13, 
S16). Congenital defects were ranked tenth for both sexes 
combined in 2019 but did not make the top ten for either 
sex separately. 
The burden for children younger than 10 years declined
profoundly between 1990 and 2019, by 57·5% (95% UI
50·3–63·1). Key drivers of this progress included large
reductions in major infectious diseases affecting
children—namely, lower respiratory infections, diarrhoeal
diseases, and meningitis, each of which declined by
more than 60% between 1990 and 2019 (figure 2). In 2019,
neonatal disorders were the leading cause of burden in
this age group, accounting for 32·4% (30·7–34·1) of the
group’s global DALYs, increasing from 23·0% (22·0–24·1)
in 1990. Six infectious diseases were also among the
top ten causes of burden in children: lower respiratory
infections (ranked second), diarrhoeal diseases (third),
malaria (fifth), meningitis (sixth), whooping cough (ninth),
and sexually transmitted infections (which were fully
accounted for by congenital syphilis in this age group;
tenth). Congenital birth defects (ranked fourth) as well
as two nutritional disorders—dietary iron deficiency
(seventh) and protein-energy malnutrition (eighth)— 
completed the top ten. The percentage change in age­
standardised DALY rates for eight of the ten leading
causes was large, ranging from a 35·4% (23·8–44·8)
decline for neonatal disorders to 78·3% (69·9–85·5)
decline for protein-energy malnutrition over the study
period. The decreases for the remaining two top-ten
causes, sexually transmitted infections and dietary iron
deficiency, were much more modest. Sub-Saharan Africa
experienced nearly half of the total DALYs (49·9%
[47·6–52·3]) for this age group in 2019. 
The change in disease burden in adolescents aged
10–24 years was much more modest (figure 2). DALYs
declined by 6·2% (95% UI 2·1–10·5) overall between
1990 and 2019. DALYs for non-communicable diseases
increased by 13·1% (9·5–16·3), whereas injuries declined
by 24·8% (19·7–29·3) and infectious diseases by 18·7%
(13·4–24·0). Three injury causes were among the top ten
causes of global DALYs in this age group in 2019: road
injuries (ranked first), self-harm (third), and interpersonal
violence (fifth; figure 2). Headache disorders, two mental
disorders (depression and anxiety), low back pain, dietary
iron deficiency, HIV/AIDS, and diarrhoeal disease were
the other causes in the top ten for adolescents. Among
the top ten causes in this age group, age-standardised
DALY rates for road injuries, self-harm, and diarrhoeal
diseases decreased by more than a third each between
1990 and 2019. As in the 0–9-year age group, the large
increase in burden due to HIV/AIDS in the 10–24-year age
group reflects a rapid increase in the first half of the study
period followed by a decline after the global scale-up of
ART; despite declining in recent years, the HIV/AIDs
burden has not yet returned to 1990 levels. The other
causes in the top ten showed small or insignificant change
(figure 2). The sex differences in the top ten rankings are
striking. The three previously mentioned injuries were
the top-ranked causes of DALYs among male adolescents
(appendix 2 figure S9), whereas headaches, depressive
disorders, and anxiety disorders were the top three causes
of DALYs among females (appendix 2 figure S10).
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Leading causes 1990 Percentage of DALYs 
1990 
Leading causes 2019 Percentage of DALYs 
2019 
Percentage change in 
number of DALYs, 
1990–2019 
Percentage change in 
age-standardised DALY 
rate, 1990–2019 
A All ages 
B 0–9 years 
Communicable, maternal, neonatal, and nutritional diseases 
Non-communicable diseases 
Injuries 
1 Neonatal disorders 10·6 (9·9 to 11·4) 1 Neonatal disorders 7·3 (6·4 to 8·4) 
2 Lower respiratory infections 8·7 (7·6 to 10·0) 2 Ischaemic heart disease 7·2 (6·5 to 7·9) 
3 Diarrhoeal diseases 7·3 (5·9 to 8·8) 3 Stroke  5·7 (5·1 to 6·2) 
4 Ischaemic heart disease 4·7 (4·4 to 5·0) 4 Lower respiratory infections 3·8 (3·3 to 4·3) 
5 Stroke 4·2 (3·9 to 4·5)  5 Diarrhoeal diseases 3·2 (2·6 to 4·0) 
6 Congenital birth defects 3·2 (2·3 to 4·8) 6 COPD 2·9 (2·6 to 3·2) 
7 Tuberculosis 3·1 (2·8 to 3·4) 7 Road injuries 2·9 (2·6 to 3·0) –31·0 (–37·1 to –25·4) 
8 Road injuries 2·7 (2·6 to 3·0) 8 Diabetes 2·8 (2·5 to 3·1) 
9 Measles 2·7 (0·9 to 5·6) 9 Low back pain 2·5 (1·9 to 3·1) 
10 Malaria 2·5 (1·4 to 4·1) 10 Congenital birth defects 2·1 (1·7 to 2·6) 
11 COPD 2·3 (1·9 to 2·5) 
2·0 (1·6 to 2·7) 
11 HIV/AIDS  1·9 (1·6 to 2·2) 
12 Protein-energy malnutrition 12 Tuberculosis 1·9 (1·7 to 2·0) 
13 Low back pain 1·7 (1·2 to 2·1) 13 Depressive disorders 
14 Self-harm 1·4 (1·2 to 1·5) 14 Malaria 1·8 (0·9 to 3·1) 
15 Cirrhosis 1·3 (1·2 to 1·5) 15 Headache disorders 
16 Meningitis 1·3 (1·1 to 1·5) 16 Cirrhosis 1·8 (1·6 to 2·0) 
17 Drowning 1·3 (1·1 to 1·4) 
1·1 (0·2 to 2·4) 
1·1 (0·8 to 1·5) 
17 Lung cancer 1·8 (1·6 to 2·0) 
18 Headache disorders 18 Chronic kidney disease 
19 Depressive disorders 19 Other musculoskeletal 
20 Diabetes 1·1 (1·0 to 1·2) 20 Age-related hearing loss 
21 Lung cancer 1·0 (1·0 to 1·1) 21 Falls 1·5 (1·4 to 1·7) 
22 Falls 1·0 (0·9 to 1·2) 
1·0 (0·7 to 1·3) 
0·9 (0·9 to 1·0) 
22 Self-harm 1·3 (1·2 to 1·5) –38·9 (–44·3 to –33·0) 
23 Dietary iron deficiency 23 Gynaecological diseases 1·2 (0·9 to 1·5) 
24 Interpersonal violence 24 Anxiety disorders 1·1 (0·8 to 1·5) 
25 Whooping cough 0·9 (0·4 to 1·7) 
0·8 (0·6 to 1·1) 
0·8 (0·8 to 0·9) 
25 Dietary iron deficiency 
27 Age-related hearing loss 26 Interpersonal violence –23·8 (–28·6 to –17·8) 
29 Chronic kidney disease 40 Meningitis 0·6 (0·5 to 0·8) 
30 HIV/AIDS 0·8 (0·6 to 1·0) 41 Protein-energy malnutrition 
32 Gynaecological diseases 0·8 (0·6 to 1·0) 46 Drowning 0·5 (0·5 to 0·6) 
34 Anxiety disorders 0·7 (0·5 to 1·0) 
0·7 (0·5 to 1·0) 
55 Whooping cough 0·4 (0·2 to 0·7) 
35 Other musculoskeletal 71 Measles 0·3 (0·1 to 0·6) 
1 Neonatal disorders 23·0 (22·0 to 24·1) 1 Neonatal disorders 32·4 (30·7 to 34·1) 
2 Lower respiratory infections 17·0 (14·9 to 19·7) 2 Lower respiratory infections 11·6 (10·5 to 12·6) 
3 Diarrhoeal diseases 13·1 (10·7 to 15·1) 3 Diarrhoeal diseases 9·3 (7·9 to 10·8) 
4 Congenital birth defects 6·6 (4·6 to 10·0) 4 Congenital birth defects 8·6 (7·4 to 10·7) 
5 Measles 5·7 (2·0 to 11·8) 5 Malaria 6·4 (3·3 to 10·8) 
6 Malaria 4·6 (2·5 to 7·5) 
4·1 (3·1 to 5·5) 
6 Meningitis 2·1 (1·8 to 2·5) 
7 Protein-energy malnutrition 7 Dietary iron deficiency –8·2 (–12·3 to –4·1) 
8 Meningitis 2·3 (2·0 to 2·7) 8 Protein-energy malnutrition 
9 Whooping cough 1·9 (0·8 to 3·8) 9 Whooping cough 1·9 (0·9 to 3·3) 
10 Drowning 1·8 (1·5 to 2·1) 10 STIs 1·4 (0·5 to 2·8) 
11 Tuberculosis 1·8 (1·5 to 2·1) 11 Measles 1·3 (0·4 to 2·7) 
12 Tetanus 1·7 (1·4 to 1·9) 12 Road injuries 1·1 (1·0 to 1·4) 
13 Road injuries 1·3 (1·1 to 1·5) 
0·9 (0·6 to 1·3) 
13 Tuberculosis 1·0 (0·9 to 1·2) 
14 Dietary iron deficiency 14 HIV/AIDS  1·0 (0·9 to 1·2) 
15 STIs 0·7 (0·2 to 1·5) 15 iNTS 1·0 (0·6 to 1·5) 
16 Typhoid and paratyphoid 0·7 (0·3 to 1·3) 16 Drowning 0·9 (0·8 to 1·1) 
17 Foreign body 0·6 (0·5 to 0·7) 17 Haemoglobinopathies 0·9 (0·7 to 1·0) 
18 HIV/AIDS 0·6 (0·5 to 0·7) 18 Typhoid and paratyphoid 0·8 (0·4 to 1·5) 
19 Encephalitis 0·5 (0·4 to 0·7) 19 Asthma 0·5 (0·4 to 0·8) 
20 Acute hepatitis 0·5 (0·4 to 0·5) 20 Foreign body 0·5 (0·4 to 0·5) 
21 Haemoglobinopathies 0·4 (0·3 to 0·6) 21 EMBID 0·5 (0·4 to 0·6) 
22 Leukaemia 0·4 (0·3 to 0·6) 22 Sudden infant death 0·5 (0·2 to 1·0) 
23 Sudden infant death 0·4 (0·2 to 0·9) 23 Idiopathic epilepsy 0·5 (0·3 to 0·6) 
24 Asthma 0·4 (0·3 to 0·5) 24 Other unspecified infectious 
25 Falls 0·4 (0·3 to 0·5)  25 Dermatitis 0·4 (0·2 to 0·7) –6·0 (–6·9 to –5·1) 
28 Idiopathic epilepsy 0·3 (0·2 to 0·4) 
0·3 (0·2 to 0·4) 
26 Leukaemia 0·4 (0·4 to 0·5) 
30 Other unspecified infectious 27 Falls 0·4 (0·3 to 0·5) 
33 iNTS 0·3 (0·1 to 0·4) 28 Encephalitis 0·4 (0·3 to 0·5) 
34 EMBID 0·3 (0·2 to 0·3) 32 Tetanus 0·3 (0·3 to 0·5) 
44 Dermatitis 0·2 (0·1 to 0·3) 39 Acute hepatitis 0·3 (0·2 to 0·3) 
–35·4 (–44·8 to –23·8) 
–69·6 (–76·3 to –61·6) 
–68·5 (–75·9 to –58·4) 
–40·1 (–55·1 to –17·9) 
–38·5 (–63·1 to –6·5) 
–61·0 (–69·2 to –51·1) 
–78·3 (–85·5 to –69·9) 
–53·2 (–75·6 to –20·4) 
–14·9 (–30·1 to 2·5) 
–90·5 (–92·9 to –87·6) 
–63·7 (–70·8 to –48·8) 
–75·5 (–80·6 to –69·2) 
–25·0 (–35·3 to –13·6) 
61·4 (20·6 to 109·3) 
–79·0 (–82·6 to –72·2) 
–13·7 (–34·3 to 14·7) 
–50·7 (–62·5 to –36·9) 
–37·5 (–50·0 to –21·5) 
–63·6 (–70·2 to –57·1) 
–22·1 (–36·1 to –6·0) 
–46·9 (–61·7 to –30·0) 
–34·0 (–49·1 to –3·8) 
–29·3 (–50·3 to 3·3) 
–55·3 (–69·5 to –37·0) 
–48·3 (–68·7 to –22·6) 
–68·5 (–77·9 to –50·2) 
–91·2 (–93·8 to –85·6) 
–74·1 (–82·6 to –61·1) 
–36·2 (–45·4 to –24·7) 
–69·1 (–75·9 to –60·9) 
–67·8 (–75·3 to –57·2) 
–41·6 (–54·6 to –17·4) 
–36·9 (–61·4 to –2·2) 
–59·7 (–68·1 to –49·3) 
–0·8 (–5·3 to 3·6) 
–78·1 (–85·0 to –68·9) 
–54·7 (–74·7 to –17·3) 
–16·3 (–30·7 to 1·7) 
–90·0 (–92·6 to –86·9) 
–61·5 (–68·7 to –45·0) 
–74·5 (–79·8 to –67·8) 
–18·6 (–35·6 to 3·6) 
68·3 (27·4 to 121·2) 
–77·6 (–81·3 to –70·1) 
–10·3 (–30·3 to 22·5) 
–46·7 (–59·1 to –31·1) 
–32·2 (–46·2 to –14·5) 
–62·9 (–69·6 to –56·2) 
–18·9 (–33·3 to –0·9) 
–50·6 (–61·6 to –29·8) 
–30·7 (–45·8 to 3·6) 
–28·4 (–48·3 to 7·8) 
2·7 (1·7 to 3·7) 
–54·8 (–67·7 to –32·9) 
–47·2 (–67·0 to –18·0) 
–67·6 (–76·7 to –47·6) 
–91·3 (–93·8 to –85·6) 
–73·1 (–81·7 to –59·1) 
2·0 (1·3 to 2·9) 
2·0 (1·7 to 2·3) 
0·4 (0·3 to 0·6) 
–57·2 (–64·4 to –48·6) 
–74·5 (–82·0 to –64·5) 
–68·2 (–71·9 to –62·8) 
–56·3 (–75·6 to –20·3) 
–90·4 (–92·8 to –87·5) 
–6·8 (–8·7 to –4·9) 
–0·1 (–1·0 to 0·7) 
–16·4 (–18·7 to –14·0) 
–14·5 (–22·5 to –7·4) 
–1·8 (–3·7 to –0·1) 
30·7 (27·6 to 34·3) 
6·3 (0·2 to 12·4) 
–16·2 (–24·0 to –8·2) 
–26·8 (–32·5 to –19·0) 
1·1 (–4·2 to 2·9) 
–37·8 (–61·9 to –6·2) 
–1·8 (–2·9 to –0·8) 
–62·8 (–66·6 to –58·0) 
58·5 (37·1 to 89·2) 
–40·0 (–52·7 to –17·1) 
–16·3 (–17·1 to –15·5) 
24·4 (18·5 to 29·7) 
–39·8 (–44·9 to –30·2) 
–64·6 (–71·7 to –54·2) 
–62·5 (–69·0 to –54·9) 
–35·2 (–40·5 to –30·5) 
–28·6 (–33·3 to –24·2) 
–32·6 (–42·1 to –21·2)–32·3 (–41·7 to –20·8) 
50·4 (39·9 to 60·2) 
32·4 (22·0 to 42·2) 
–56·7 (–64·2 to –47·5) 
–57·5 (–66·2 to –44·7) 
25·6 (15·1 to 46·0) 
2·4 (–6·9 to 10·8) 
147·9 (135·9 to 158·9) 
46·9 (43·3 to 50·5) 
–37·3 (–50·6 to –12·8) 
127·7 (97·3 to 171·7) 
–41·0 (–47·2 to –33·5) 
61·1 (56·9 to 65·0) 
–29·4 (–56·9 to 6·6) 
56·7 (52·4 to 62·1) 
33·0 (22·4 to 48·2) 
69·1 (53·1 to 85·4) 
93·2 (81·6 to 105·0) 
128·9 (122·0 to 136·3) 
82·8 (75·2 to 88·9) 
47·1 (31·5 to 61·0) 
–5·6 (–14·2 to 3·7) 
48·7 (45·8 to 51·8) 
53·7 (48·8 to 59·1) 
13·8 (10·5 to 17·2)1·1 (0·8 to 1·5) 
1·6 (1·2 to 2·1) 
1·6 (1·2 to 2·1) 
1·6 (1·5 to 1·8) 
1·8 (0·4 to 3·8) 
1·8 (1·4 to 2·4) 
–89·8 (–92·3 to –86·8) 
–54·5 (–74·6 to –16·9) 
–60·6 (–65·2 to –53·6) 
–71·1 (–79·6 to –59·7) 
–51·3 (–59·4 to –42·0) 
10·2 (3·2 to 19·2)1·1 (1·0 to 1·2) 
0·6 (0·5 to 0·7) 
(Figure 2 continues on next page) 
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Maternal disorders, gynaecological disorders, and dietary
iron deficiency were also in the top ten causes for females
in this relatively young age group (appendix 2 figure S10). 
Five causes that were in the top ten for ages 10–24
in 2019 were also in the top ten in the 25–49 age group:
road injuries (ranked first), HIV/AIDS (second), low back
pain (fourth), headache disorders (fifth), and depressive
disorders (sixth; figure 2). Tuberculosis and four non­
communicable causes—ischaemic heart disease, gynae­
cological disorders, other musculoskeletal disorders, and
stroke—completed the top ten rankings. There were
substantial improvements since 1990 in DALY rates of
Leading causes 1990 Percentage of DALYs 
1990 
Leading causes 2019 Percentage of DALYs 
2019 
Percentage change in 
number of DALYs, 
1990–2019 
Percentage change in 
age-standardised DALY 
rate, 1990–2019 
C 10–24 years 
D 25–49 years 
Communicable, maternal, neonatal, and nutritional diseases 
Non-communicable diseases 
Injuries 
1 Road injuries  7·8 (6·9 to 8·8) 1 Road injuries  6·6 (5·6 to 7·7) 
2 Self-harm 4·9 (4·1 to 5·6) 2 Headache disorders 5·0 (0·6 to 10·9) 
3 Headache disorders 3·8 (0·4 to 8·2) 3 Self-harm 3·7 (3·1 to 4·5) 
4 Tuberculosis 3·6 (3·1 to 4·1) 4 Depressive disorders  3·7 (2·6 to 5·0) 
5 Diarrhoeal diseases 3·2 (2·1 to 4·9) 5 Interpersonal violence –15·4 (–21·3 to –7·9) 
6 Interpersonal violence 6 Anxiety disorders  3·3 (2·3 to 4·4) 
7 Maternal disorders 3·0 (2·6 to 3·4) 7 Low back pain 3·2 (2·2 to 4·3) –12·0 (–13·3 to –10·6) 
8 Depressive disorders  2·8 (2·0 to 3·9) 8 Dietary iron deficiency –3·5 (–9·5 to 2·0) 
9 Low back pain 2·8 (1·9 to 3·8) 9 HIV/AIDS 2·6 (1·9 to 3·5) 
10 Drowning 2·7 (2·3 to 3·2) 10 Diarrhoeal diseases 2·6 (1·9 to 3·6) 
11 Typhoid and paratyphoid 2·6 (1·2 to 4·9) 11 Neonatal disorders 2·3 (1·8 to 2·8) 
12 Anxiety disorders  2·6 (1·8 to 3·5) 12 Tuberculosis 2·1 (1·8 to 2·5) 
13 Dietary iron deficiency 13 Gynaecological diseases 1·9 (1·4 to 2·6) 
14 Malaria 2·1 (1·3 to 3·3) 14 Typhoid and paratyphoid 1·8 (0·8 to 3·3) 
15 Lower respiratory infections 1·7 (1·4 to 2·0) 15 Maternal disorders 1·8 (1·5 to 2·2) 
16 Conflict and terrorism 1·5 (1·3 to 1·9) 16 Malaria 1·8 (1·0 to 3·0) 
17 Gynaecological diseases 1·5 (1·1 to 2·1) 17 Conduct disorder 1·8 (1·1 to 2·6) 
18 Falls 1·5 (1·3 to 1·6) 18 Drug use disorders  1·6 (1·3 to 2·1) 
19 Congenital birth defects 1·5 (1·3 to 1·7) 19 Acne vulgaris 1·6 (1·0 to 2·4) 
20 Idiopathic epilepsy  1·4 (1·1 to 1·8) 20 Idiopathic epilepsy  1·6 (1·2 to 2·1) –11·4 (–22·8 to 4·6) 
21 Conduct disorder 1·3 (0·8 to 2·0) 21 Congenital birth defects 1·5 (1·3 to 1·7) –21·2 (–29·7 to –10·5) 
22 Drug use disorders  1·3 (1·0 to 1·6) 22 Falls 1·4 (1·3 to 1·6) –23·9 (–30·9 to –16·7) 
23 Asthma 1·2 (1·0 to 1·6) 23 Drowning 1·4 (1·2 to 1·7) 
24 Stroke 1·2 (1·0 to 1·3) 24 Lower respiratory infections  1·4 (1·2 to 1·7) 
25 Meningitis 1·1 (1·0 to 1·3) 25 Age-related hearing loss 
27 Acne vulgaris 1·1 (0·7 to 1·6) 27 Asthma 1·3 (1·0 to 1·8) –18·0 (–23·8 to –12·4) 
28 Age-related hearing loss 30 Stroke 1·1 (0·9 to 1·3) 
33 HIV/AIDS 0·9 (0·6 to 1·5) 34 Meningitis 0·9 (0·7 to 1·1) 
35 Neonatal disorders 0·9 (0·7 to 1·1) 46 Conflict and terrorism 0·6 (0·5 to 0·8) 
1 Road injuries 5·6 (5·1 to 6·1) 1 Road injuries  5·1 (4·6 to 5·7) 
2 Tuberculosis 5·5 (4·8 to 6·2) 2 HIV/AIDS 4·8 (4·0 to 5·9) 
3 Ischaemic heart disease 4·4 (3·8 to 4·9) 3 Ischaemic heart disease 4·7 (4·0 to 5·4) 
4 Low back pain 3·9 (2·9 to 5·1) 4 Low back pain  3·9 (2·9 to 5·0) 
5 Self-harm 3·8 (3·3 to 4·4) 5 Headache disorders 3·7 (0·8 to 7·7) 
6 Stroke 3·5 (3·1 to 3·9) 6 Depressive disorders  3·5 (2·5 to 4·5) 
7 Headache disorders 3·1 (0·7 to 6·4) 7 Gynaecological diseases 3·3 (2·5 to 4·2) 
8 Depressive disorders 3·0 (2·2 to 3·9) 8 Other musculoskeletal 
9 Cirrhosis 2·8 (2·5 to 3·2) 9 Stroke 3·2 (2·8 to 3·6) –31·0 (–37·9 to –24·6) 
10 Gynaecological diseases 2·8 (2·2 to 3·7) 10 Tuberculosis 3·0 (2·6 to 3·4) 
11 Maternal disorders 2·6 (2·3 to 2·9) 11 Self-harm 2·9 (2·4 to 3·4) –37·2 (–43·2 to –30·9) 
12 Interpersonal violence 12 Cirrhosis 2·8 (2·4 to 3·2) 
13 HIV/AIDS 2·3 (1·6 to 3·2) 13 Interpersonal violence 
14 Other musculoskeletal 14 Diabetes 2·2 (1·9 to 2·5) 
15 Diarrhoeal diseases 2·0 (1·3 to 3·1) 15 Anxiety disorders 2·0 (1·4 to 2·7) 
16 Falls 1·8 (1·6 to 2·0) 16 Drug use disorders 1·9 (1·5 to 2·2) 
17 Anxiety disorders 1·7 (1·2 to 2·2) 17 Falls 1·8 (1·6 to 2·0) 
18 Alcohol use disorders 18 Chronic kidney disease 
19 Neck pain 1·3 (0·9 to 2·0) 19 Neck pain  1·6 (1·1 to 2·4) 
20 Diabetes 1·3 (1·2 to 1·5) 20 Alcohol use disorders 
21 Chronic kidney disease 21 Age-related hearing loss 
22 Drug use disorders 1·3 (1·0 to 1·6) 22 Schizophrenia 1·5 (1·1 to 1·9) 
23 Schizophrenia 1·3 (0·9 to 1·6) 23 Maternal disorders 1·4 (1·2 to 1·6) 
24 Age-related hearing loss 24 Diarrhoeal diseases 1·3 (1·0 to 1·9) 
25 Lower respiratory infections  1·2 (1·1 to 1·4) 25 Oral disorders 1·2 (0·7 to 2·1) 
32 Oral disorders 1·0 (0·5 to 1·6) 27 Lower respiratory infections 1·2 (1·0 to 1·4) –23·1 (–30·2 to –16·0) 
2·8 (0·5 to 5·1) 
–46·2 (–59·0 to –29·6) 
–53·4 (–60·5 to –47·2) 
–0·9 (–2·0 to 0·2) 
–0·5 (–3·1 to 1·9) 
–20·9 (–24·2 to –17·9) 
–3·6 (–6·0 to –1·5) 
0·7 (–7·3 to 8·4) 
–18·0 (–23·4 to –13·5) 
25·4 (19·3 to 31·6) 
1·1 (0·0 to 2·1) 
29·2 (21·1 to 36·0) 
–24·4 (–29·0 to –19·0) 
–23·8 (–30·1 to –15·1) 
–55·5 (–60·2 to –50·5) 
26·7 (23·4 to 30·5) 
–4·5 (–6·3 to –2·5) 
–4·9 (–6·4 to –3·4) 
0·2 (–3·7 to 2·3) 
–19·2 (–20·5 to –18·0) 
–18·5 (–26·7 to –10·1) 
72·2 (52·4 to 91·9) 
–22·5 (–30·1 to –16·2) 
–68·5 (–71·6 to –65·1) 
–38·3 (–45·0 to –30·4) 
–27·6 (–34·8 to –19·4) 
–1·2 (–5·7 to 3·2) 
–34·1 (–41·6 to –25·5) 
–58·8 (–63·2 to –53·9) 
18·1 (16·7 to 19·5) 
0·6 (–4·8 to 6·2) 
4·4 (2·3 to 6·3) 
–31·9 (–59·0 to –3·6) 
–52·5 (–60·2 to –45·3) 
–46·2 (–54·9 to –38·5) 
–1·4 (–4·2 to 1·0) 
–53·8 (–59·1 to –47·7) 
103·6 (78·4 to 128·5) 
–37·0 (–50·2 to –17·0) 
112·8 (84·3 to 141·9) 
–2·0 (–3·8 to –0·1) 
0·0 (–2·8 to 2·4) 
–40·5 (–47·2 to –32·8) 
3·3 (0·2 to 5·6) 
–33·6 (–40·4 to –27·7)–20·1 (–28·3 to –12·9) 
24·6 (20·6 to 27·1) 
–28·4 (–36·3 to –18·9) 
20·7 (17·4 to 23·5) 
2·1 (–5·0 to 11·1) 
17·9 (15·7 to 20·3) 
6·0 (4·4 to 7·6) 
15·9 (8·6 to 22·4) 
159·0 (115·4 to 211·1) 
–25·7 (–40·1 to –0·3) 
143·6 (114·3 to 174·6) 
–44·3 (–50·7 to –36·9) 
19·1 (15·8 to 22·0) 
–35·5 (–46·0 to –26·4) 
–42·7 (–51·9 to –33·8) 
–19·4 (–50·8 to 15·8) 
24·7 (22·2 to 27·0) 
21·8 (15·2 to 28·7) 
41·5 (39·8 to 43·2) 
6·5 (–7·1 to 25·7) 
–5·6 (–15·6 to 7·4) 
–8·4 (–16·9 to 0·4) 
–50·7 (–55·9 to –44·7) 
–20·9 (–29·9 to –10·5) 
18·6 (13·4 to 24·2)1·3 (0·9 to 1·8) 
2·6 (1·9 to 3·4) 
3·5 (2·9 to 4·1) 
–1·1 (–8·3 to 5·1) 
–12·8 (–21·5 to –2·9) 
–26·0 (–34·0 to –16·4) 
–62·1 (–65·7 to –57·9) 
23·2 (11·1 to 33·2) 
176·2 (131·1 to 244·3) 
42·7 (28·4 to 57·3) 
33·0 (29·2 to 36·9) 
61·2 (56·5 to 64·5) 
53·2 (49·3 to 56·8) 
52·7 (49·7 to 56·0) 
107·1 (101·0 to 114·3) 
19·9 (8·0 to 31·1) 
–27·0 (–34·7 to –18·7) 
–0·9 (–10·3 to 9·1) 
29·6 (19·0 to 44·5) 
18·1 (10·7 to 26·5) 
123·9 (110·1 to 135·3) 
61·6 (57·5 to 65·4) 
92·0 (82·7 to 102·5) 
34·4 (25·8 to 41·7) 
67·3 (53·9 to 80·3) 
60·2 (52·4 to 67·9) 
28·2 (22·9 to 33·2) 
64·3 (58·7 to 69·1) 
59·6 (57·5 to 61·9) 
–28·9 (–39·6 to –19·2) 
–13·5 (–32·6 to 15·5) 
70·7 (66·4 to 74·1) 
1·5 (1·1 to 2·1) 
1·6 (1·3 to 1·9) 
1·6 (1·4 to 1·8) 
2·3 (2·0 to 2·6) 
3·2 (2·3 to 4·2) 
26·8 (15·2 to 38·5) 
3·2 (2·8 to 3·6) 
2·1 (1·6 to 2·8) 
1·1 (0·7 to 1·5) 
2·5 (2·3 to 2·8) 
2·0 (1·5 to 2·8) 
1·7 (1·4 to 2·0) 
1·3 (0·9 to 1·7) 
1·3 (1·2 to 1·4) 
(Figure 2 continues on next page) 
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Leading causes 1990 Percentage of DALYs 
1990 
Leading causes 2019 Percentage of DALYs 
2019 
Percentage change in 
number of DALYs, 
1990–2019 
Percentage change in 
age-standardised DALY 
rate, 1990–2019 
E 50–74 years 
F 75 years and older 
Communicable, maternal, neonatal, and nutritional diseases 
Non-communicable diseases 
Injuries 
1 Ischaemic heart disease 12·5 (11·6 to 13·4) 1 Ischaemic heart disease 11·8 (10·7 to 12·9) 
2 Stroke 10·9 (10·0 to 11·8) 2 Stroke  9·3 (8·5 to 10·1) 
3 COPD 6·5 (5·5 to 7·1) 3 Diabetes 5·1 (4·6 to 5·7) 
4 Tuberculosis 4·0 (3·6 to 4·4) 4 COPD 4·7 (4·2 to 5·2) –45·9 (–51·4 to –36·2) 
5 Lung cancer 3·6 (3·3 to 3·9) 5 Lung cancer 3·9 (3·4 to 4·3) 
6 Diabetes 3·1 (2·8 to 3·4) 6 Low back pain 3·1 (2·3 to 4·0) 
7 Cirrhosis 2·8 (2·6 to 3·1) 7 Cirrhosis 2·7 (2·4 to 3·0) 
8 Low back pain 2·8 (2·1 to 3·7) 8 Chronic kidney disease 
9 Diarrhoeal diseases 2·6 (1·6 to 4·0) 9 Age-related hearing loss 
10 Stomach cancer 2·4 (2·2 to 2·6) 10 Road injuries 2·1 (1·9 to 2·3) 
11 Road injuries 1·9 (1·8 to 2·0) 11 Other musculoskeletal 
12 Lower respiratory infections 1·8 (1·6 to 2·0) 12 Tuberculosis 1·9 (1·7 to 2·1) 
13 Age-related hearing loss 13 Lower respiratory infections 1·8 (1·6 to 1·9) 
14 Chronic kidney disease 14 Depressive disorders 
15 Asthma 1·5 (1·2 to 1·9) 15 Colorectal cancer 1·7 (1·6 to 1·9) 
16 Hypertensive heart disease 16 Falls 1·7 (1·5 to 2·0) 
17 Falls 1·4 (1·3 to 1·6) 17 Stomach cancer 1·7 (1·5 to 1·9) –48·1 (–536 to –42·0) 
18 Colorectal cancer 1·4 (1·3 to 1·5) 18 Osteoarthritis 1·5 (0·8 to 2·9) 
19 Depressive disorders 19 Blindness and vision loss 
20 Blindness and vision loss 20 Breast cancer 1·4 (1·3 to 1·5) 
21 Liver cancer 1·2 (1·0 to 1·3) 21 Diarrhoeal diseases 1·4 (0·9 to 2·1) 
22 Breast cancer 1·2 (1·1 to 1·2) 22 Hypertensive heart disease 
23 Oesophageal cancer 1·1 (0·9 to 1·2) 23 Headache disorders 
24 Osteoarthritis 1·1 (0·6 to 2·2) 24 Oral disorders 1·2 (0·8 to 1·8) 
25 Self-harm 1·1 (1·0 to 1·2) 25 Neck pain 1·1 (0·7 to 1·7) 
26 Other musculoskeletal 27 Oesophageal cancer 1·0 (0·9 to 1·1) 
28 Oral disorders 1·0 (0·6 to 1·5) 28 Asthma 1·0 (0·8 to 1·1) 
29 Headache disorders 29 Liver cancer 0·9 (0·8 to 1·0) –39·9 (–48·5 to –29·5) 
32 Neck pain 0·8 (0·5 to 1·2) 31 Self-harm 0·9 (0·8 to 1·0) 
1 Ischaemic heart disease 18·6 (17·1 to 19·7) 1 Ischaemic heart disease 16·2 (14·6 to 17·6) 
2 Stroke 15·5 (14·3 to 16·7) 2 Stroke 13·0 (11·7 to 14·0) 
3 COPD 9·9 (8·6 to 10·7) 3 COPD 8·5 (7·5 to 9·2) 
4 Alzheimer's disease 3·8 (1·7 to 8·6) 4 Alzheimer's disease 5·6 (2·6 to 12·2) 
5 Lower respiratory infections 3·3 (3·0 to 3·6) 5 Diabetes 4·0 (3·6 to 4·3) 
6 Diarrhoeal diseases 3·1 (2·0 to 4·5) 6 Lower respiratory infections  3·3 (2·9 to 3·6) 
7 Diabetes 2·6 (2·4 to 2·9) 7 Lung cancer 2·6 (2·3 to 2·8) 
8 Hypertensive heart disease 8 Falls 2·6 (2·2 to 2·9) 
9 Age-related hearing loss 9 Chronic kidney disease 
10 Lung cancer 1·9 (1·8 to 2·0) 10 Age-related hearing loss 
11 Falls 1·8 (1·6 to 2·1) 11 Hypertensive heart disease 
12 Tuberculosis 1·8 (1·6 to 2·1) 12 Diarrhoeal diseases 1·9 (1·2 to 3·0) 
13 Low back pain 1·7 (1·2 to 2·3) 13 Low back pain 1·8 (1·3 to 2·4) 
14 Chronic kidney disease 14 Colorectal cancer 1·7 (1·5 to 1·8) 
15 Stomach cancer 1·6 (1·4 to 1·7) 15 Blindness and vision loss 
16 Blindness and vision loss 16 Atrial fibrillation 1·3 (1·1 to 1·5) 
17 Colorectal cancer 1·4 (1·3 to 1·5) 17 Stomach cancer 1·3 (1·1 to 1·4) 
18 Asthma 1·2 (1·0 to 1·7) 18 Prostate cancer 1·1 (1·0 to 1·4) 
19 Cirrhosis 1·2 (1·0 to 1·3) 19 Cirrhosis 1·1 (1·0 to 1·2) 
20 Prostate cancer 1·0 (0·8 to 1·2) 20 Parkinson's disease 
21 Atrial fibrillation 1·0 (0·8 to 1·2) 21 Osteoarthritis 1·1 (06 to 21) 
22 Osteoarthritis 0·9 (0·5 to 1·7) 22 Oral disorders 0·9 (0·6 to 1·3) 
23 Oral disorders 0·8 (0·6 to 1·2) 23 Tuberculosis 0·9 (0·8 to 1·0) 
24 Parkinson's disease 24 Asthma 0·8 (0·7 to 1·0) –46·2 (–55·9 to –39·8) 
25 Upper digestive diseases 0·8 (0·7 to 0·9) 25 Road injuries 0·8 (0·7 to 0·9) 
26 Road injuries 0·7 (0·6 to 0·8) 32 Upper digestive diseases  0·6 (0·5 to 0·6) 
1·7 (1·2 to 2·3) 
1·6 (1·4 to 1·7) 
1·5 (1·2 to 1·7) 
1·3 (0·9 to 1·7) 
1·2 (0·9 to 1·6) 
1·1 (0·7 to 1·5) 
0·9 (0·3 to 1·9) 
–41·0 (–45·5 to –34·5) 
–51·8 (–58·3 to –46·0) 
–32·1 (–41·9 to –16·1) 
5·7 (3·0 to 8·5) 
–7·4 (–9·6 to –5·1) 
–1·2 (–7·4 to 2·3) 
–33·8 (–41·7 to –23·4) 
–61·0 (–72·1 to –45·8) 
–9·5 (–16·9 to –2·5) 
–8·6 (–12·0 to –5·0) 
4·1 (28 to 5·4) 
38·2 (18·9 to 71·9) 
–1·3 (–14·3 to 11·2) 
22·2 (5·2 to 44·0) 
20·4 (11·3 to 33·7) 
115·9 (110·5 to 122·2) 
90·5 (86·0 to 94·7) 
102·5 (88·7 to 108·2) 
36·7 (20·8 to 58·8) 
–21·0 (–42·4 to 11·9) 
85·0 (69·9 to 99·4) 
88·8 (81·9 to 95·8) 
113·6 (110·9 to 116·4) 
6·3 (–5·0 to 18·9) 
–8·4 (–14·1 to –2·6) 
–5·1 (–12·1 to 1·2) 
1·5 (0·2 to 2·9) 
–27·5 (–33·3 to –21·5) 
–64·7 (–68·9 to –59·4) 
33·6 (280 to 40·2) 
–15·2 (–23·2 to –9·9) 
–2·6 (–4·9 to –0·5) 
12·1 (3·7 to 19·5) 
–29·1 (–34·7 to –23·0) 
–15·9 (–16·9 to –14·9) 
–19·8 (–27·3 to –12·1) 
24·5 (18·5 to 30·4) 
–36·3 (–42·1 to –30·8) 
–29·1 (–34·2 to –24·1)46·1 (35·6 to 56·4) 
31·5 (19·5 to 42·9) 
156·1 (143·4 to 167·9) 
12·0 (0·9 to 32·3) 
64·3 (48·8 to 80·2) 
72·1 (70·0 to 74·3) 
44·6 (33·2 to 57·1) 
130·2 (113·0 to 145·6) 
100·8 (96·0 to 104·9) 
72·9 (56·5 to 83·9) 
172·0 (160·6 to 187·4) 
–27·8 (–36·2 to –16·9) 
49·8 (37·9 to 62·4) 
107·3 (104·7 to 110·1) 
95·1 (80v8 to 108·2) 
88·3 (76·5 to 100·0) 
1·2 (0·4 to 2·5) 
1·3 (1·0 to 1·5) 
1·4 (1·1 to 2·0) 
1·7 (1·3 to 2·3) 
1·9 (1·4 to 2·6) 
2·3 (2·1 to 2·5) 
2·2 (1·5 to 3·0) 
–32·4 (–35·8 to –29·4) 
–33·4 (–38·3 to –28·5) 
–31·0 (–37·1 to –21·9) 
2·6 (–2·1 to 6·6) 
23·1 (18·6 to 27·5) 
–25·3 (–29·3 to –20·4) 
16·4 (7·4 to 24·9) 
6·4 (0·4 to 13·3) 
21·6 (12·6 to 27·4) 
–2·2 (–4·3 to –0·2) 
–15·1 (–31·5 to –5·0) 
–51·0 (–64·9 to –30·4) 
–12·5 (–13·8 to –11·3) 
–4·5 (–9·7 to 0·1) 
–7·4 (–9·9 to –4·8) 
–1·8 (–6·9 to 2·5) 
–32·9 (–37·5 to –28·0) 
–8·5 (–14·6 to 2·1) 
–21·3 (–30·2 to –13·5) 
6·0 (0·0 to 11·1) 
0·8 (–0·4 to 2·1) 
–10·9 (–12·9 to –8·8) 
–59·2 (–64·0 to –50·3) 
–9·3 (–13·5 to –5·9) 
–43·8 (–48·4 to –38·7)34·0 (22·8 to 46·2) 
110·0 (99·8 to 118·1) 
25·2 (3·2 to 41·2) 
–6·3 (–16·9 to 14·6) 
112·0 (106·4 to 117·6) 
139·5 (136·5 to 142·6) 
153·7 (138·7 to 166·6) 
82·3 (62·1 to 100·9) 
117·0 (102·1 to 142·3) 
55·0 (43·8 to 66·6) 
148·6 (134·8 to 161·9) 
124·7 (119·3 to 130·7) 
126·9 (113·4 to 138·3) 
105·7 (100·2 to 111·4) 
15·1 (–16·8 to 65·3) 
106·0 (68·5 to 131·7) 
137·8 (132·0 to 143·9) 
196·0 (173·9 to 211·1) 
166·4 (151·1 to 183·4) 
164·3 (143·6 to 183·8) 
87·4 (76·2 to 99·6) 
190·7 (179·4 to 201·0) 
180·0 (168·0 to 194·7) 
63·6 (49·1 to 86·1) 
60·5 (48·7 to 72·5) 
66·6 (57·7 to 74·2) 
2·5 (2·3 to 2·7) 
2·5 (1·9 to 3·3) 
2·4 (1·8 to 2·7) 
1·7 (1·3 to 2·2) 
1·1 (1·0 to 1·2) 
0·8 (0·8 to 0·9) 
1·4 (1·1 to 1·8) 
1·6 (1·5 to 1·8) 
2·0 (1·5 to 2·7) 
2·3 (1·9 to 2·5) 
· 
· 
Figure 2: Leading 25 Level 3 causes of global DALYs and percentage of total DALYs (1990 and 2019), and percentage change in number of DALYs and 
age-standardised DALY rates from 1990 to 2019 for both sexes combined for all ages (A), children younger than 10 years (B), and ages 10–24 years (C), 
25–49 years (D), 50–74 years (E), and 75 years and older (F) 
Causes are connected by lines between time periods; solid lines are increases in rank and dashed lines are decreases. Age-related hearing loss=age-related and other
hearing loss. Alzheimer’s disease=Alzheimer’s disease and other dementias. Atrial fibrillation=atrial fibrillation and flutter. Cirrhosis=cirrhosis and other chronic liver
diseases. COPD=chronic obstructive pulmonary disease. EMBID=endocrine, metabolic, blood, and immune disorders. DALY=disability-adjusted life-year. iNTS=invasive
non-typhoidal salmonella. Haemoglobinopathies=haemoglobinopathies and haemolytic anaemias. Lung cancer=tracheal, bronchus, and lung cancer. Other
musculoskeletal=other musculoskeletal disorders. Other unspecified infectious=other unspecified infectious diseases. Sudden infant death=sudden infant death
syndrome. STI=sexually transmitted infections excluding HIV. 
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tuberculosis, road injuries, stroke, and, to a lesser extent,
low back pain and ischaemic heart disease. For similar
reasons as in the previous age group, HIV/AIDS
DALY rates increased substantially. The increase in the
residual “other musculoskeletal disorder” category is
more difficult to interpret, as it is a collection of several
individual diseases. HIV/AIDS, ischaemic heart disease,
stroke, and headache disorders appeared in the top-ten
rankings for DALYs for both males and females in 2019.
Three injury causes (road injuries, self-harm, and inter­
personal violence) and cirrhosis ranked prominently
among males but not females. Among females, gynae­
cological disorders, depressive disorders, other musculo­
skeletal disorders, maternal disorders, and anxiety
disorders were top ten causes (appendix 2 figures S9, S10). 
In 2019, the ten leading causes of DALYs in age groups
50–74 years and 75 years and older largely overlapped.
Ischaemic heart disease and stroke were ranked first
and second, respectively, in both age groups. Chronic
obstructive pulmonary disease (COPD), diabetes, lung
cancer, chronic kidney disease, and age-related hearing
loss appeared in the top ten in both age groups. For ages
50–74 years, low back pain, cirrhosis, and road injuries
were the remaining top-ten-ranking causes of DALYs,
whereas Alzheimer’s disease and other dementias, lower
respiratory infections, and falls appeared in the top ten for
those aged 75 years and older. The most notable changes
in top ten causes in these two age groups between
1990 and 2019 were large declines in age-standardised
DALY rates for ischaemic heart disease, stroke, COPD,
cirrhosis, and road injuries, but increases in DALY rates
for diabetes and chronic kidney disease. There was a
decline in age-standardised lung cancer rates for ages
50–74 years, but an increase in the oldest age category. The
ten leading causes for DALYs by sex in both of these older
age groups largely overlapped in 2019. Among 50–74-year­
olds, breast cancer, other musculoskeletal disorders, and
depressive disorders appeared in the top ten for females
only, while road injuries, cirrhosis, and tuberculosis made
it into the top ten for males. For the oldest age group, falls
and hypertensive heart disease ranked in the top ten
among females, but not males; lung cancer and prostate
cancer ranked among the top ten in males (appendix 2
figures S9, S10). 
National trends 
Countries and territories vary widely in their stages of the
epidemiological transition. With increasing SDI, we
expect to see a shift in the burden of disease from commu­
nicable, maternal, neonatal, and nutritional diseases
towards non-communicable causes. We also expect to
see a shift towards a larger fraction of the burden due to
YLDs compared with YLLs. These two major trends can
be summarised by the percentage of all-cause DALYs
made up of non-communicable disease and injury YLDs.
Figure 3 shows this proportion across 204 countries and
territories in 1990 and 2019. In 2019, this measure of the
epidemiological transition ranged from 8·4% (95% UI
6·2–10·9) in Chad to 56·9% (48·7–64·3) in Qatar.
The values in 1990 ranged from 3·5% (2·6–4·7) in Niger
to 47·5% (37·6–56·0) in Andorra. In 2019, non-commu­
nicable and injury YLDs contributed to more than half of
all disease burden in 11 countries. All but two countries,
Ukraine and Lesotho, had higher ratios in 2019 compared
with 1990. 
When comparing the annualised rate of change in age­
standardised DALY rates for all causes except HIV/AIDS,
natural disasters, and war and conflict between the time
periods 1990–2010 and 2010–19 for each country and
territory, the rate, as shown by a simple linear regression
line, is steeper in the latter time period, suggesting that
change has accelerated over the last decade in countries
and territories at the lower end of the SDI range (figure 4).
Improvements have started to stagnate, or even reverse,
in countries with higher SDI, as is the case in Dominica,
the Dominican Republic, Guam, Jamaica, Saint Lucia,
Saint Vincent and the Grenadines, Ukraine, the USA, and
Venezuela. Countries with greater than 2% annual reduc­
tions in age-standardised DALY rates over both time
periods were Ethiopia, Angola, Burundi, Malawi, Sudan,
Myanmar, Laos, and Bangladesh. Four countries from the
former Soviet Union—Russia, Belarus, Kazakhstan, and
Uzbekistan—experienced increases in age-standardised
DALY rates between 1990 and 2010, but recovered in
the following decade; Russia, Kazakhstan, and Belarus
experienced an estimated annual decline of 2% or greater
between 2010 and 2019, and Uzbekistan experienced an
estimated 1·5% annual decline. Another former Soviet
Union republic, Ukraine, saw modest decline in the
1990 to 2010 period, but a worsening trend in the decade
after. 
Cause-specific trends 
Two-page cause-specific summaries provide detailed 
results on mortality, prevalence, incidence, YLLs, YLDs, 
and DALYs for a selection of diseases, injuries, and 
impairments in the GBD cause hierarchy. These sum­
maries include 2019 counts, age-standardised rates, and 
rankings; the fraction of DALYs attributed to risk factors; 
patterns over time and age; and the relationship between 
SDI and DALY rates by country or territory. They were 
written to increase the accessibility to and transparency 
of GBD estimates for each cause. Summaries for select 
causes are highlighted in print (pp S2–213); summaries
for all diseases, injuries, and impairments can be found 
online. 
Discussion 
Main findings 
Global health has steadily improved over the past
30 years, as measured by changes in age-standardised
DALY rates. While health has improved, after accounting
for population growth and ageing, the absolute number
of DALYs has remained stable. The shift to a much
For all two-page summaries see 
https://www.thelancet.com/ 
gbd/summaries 
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Caribbean and central America Persian Gulf West Africa Balkan Peninsula 
Eastern 
MediterraneanSoutheast Asia 
Northern Europe 
Caribbean and central America Persian Gulf West Africa Balkan Peninsula 
Eastern 
MediterraneanSoutheast Asia 
Northern Europe 
B 2019 
A 1990 
YLD proportion of DALYs 
<10% 
10% to 14% 
15% to 19% 
20% to 24% 
25% to 29% 
30% to 34% 
35% to 39% 
40% to 44% 
45% to 49% 
≥50% 
Figure 3: Proportion of total DALYs contributed by injury and non-communicable disease YLDs, by country or territory, 2019 
Proportions were rounded to the nearest whole number. DALY=disability-adjusted life-year. YLD=year lived with disability. 
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Figure 4: Annualised rate of change in age-standardised DALY rates for all causes excluding HIV/AIDS, natural disasters, and war and conflict, and SDI by 
country or territory, for 1990–2010 (A) and 2010–19 (B) 
A simple linear regression line is shown in each figure for the relationship between annualised rate of change and the average SDI value of each country and territory 
for each time period. AFG=Afghanistan. AGO=Angola. ARE=United Arab Emirates. BDI=Burundi. BGD=Bangladesh. BLR=Belarus. BOL=Bolivia. BTN=Bhutan. 
CHN=China. CIV=Côte d’Ivoire. CMR=Cameroon. COD=Democratic Republic of the Congo. DALY=disability-adjusted life-year. DMA=Dominica. DOM=Dominican 
Republic. ERI=Eritrea. ETH=Ethiopia. GHA=Ghana. GNB=Guinea-Bissau. GNQ=Equatorial Guinea. GTM=Guatemala. GUM=Guam. IND=India. JAM=Jamaica. 
KAZ=Kazakhstan. KHM=Cambodia. KOR=South Korea. KNA=Saint Kitts and Nevis. LAO=Laos. LBR=Liberia. LCA=Saint Lucia. LSO=Lesotho. MDA=Moldova. 
MDV=Maldives. MMR=Myanmar. MOZ=Mozambique. MRT=Mauritania. MWI=Malawi. NER=Niger. NGA=Nigeria. NPL=Nepal. NRU=Nauru. OMN=Oman. PER=Peru. 
RUS=Russia. RWA=Rwanda. SDN=Sudan. SGP=Singapore. SLE=Sierra Leone. SOM=Somalia. SWZ=eSwatini. TGO=Togo. TLS=Timor-Leste. TUR=Turkey. UKR=Ukraine. 
UZB=Uzbekistan. VCT=Saint Vincent and the Grenadines. VEN=Venezuela. YEM=Yemen. ZAF=South Africa. ZWE=Zimbabwe. SDI=Socio-demographic Index. 
greater number of DALYs occurring at older ages, despite
reductions in age-standardised DALY rates, illustrates
the importance of understanding how ageing shapes
future health needs. Policy makers should remain aware
that the number of DALYs represents the burden of
disease that the world’s health systems must manage. 
Although most diseases showed a pattern of stable or 
slowly changing rates of death and disability over the 
study period, there are some notable exceptions. Deaths 
due to drug use disorders have risen sharply over the 
past decade. In 2019, more than half of all global overdose 
deaths occurred in the USA. Liberal prescribing of high-
dose opioids, inadequate provision of opioid substitution 
therapy, and the lacing of street drugs with highly 
potent opioids such as fentanyl are considered major 
contributors to this public health crisis.14–17 By contrast, a 
positive, rapid change in disease rates has taken place in 
Egypt, where close to 80% of the population aged 12 years 
and older has been screened for hepatitis C, and those 
with detectable virus are treated with a low-cost treatment 
regimen.18,19 We estimated that the number of cases of 
chronic hepatitis C has dropped by 65·9% (95% UI 
51·1–79·7) since screening and treatment were initiated 
through regular health services in 2014 and an enhanced 
national screening programme for the whole population 
aged 12 years and older was established in 2019.19 Egypt 
had the highest prevalence of chronic hepatitis C in the 
world, ascribed to iatrogenic infection during treatment 
campaigns for schistosomiasis in the 1960s and 1970s.20–22 
The sharp decline in chronic infections in Egypt is 
expected to be reflected in a large decline in deaths 
from cirrhosis and liver cancer in coming years. Unlike 
hepatitis B vaccination in children, where the effect of 
intervention cannot be expected until several decades 
later, removal of hepatitis C virus in the adult population 
leads to more immediate health impact. 
In children younger than 10 years, the decline in 
neonatal disorders was slower than for the major 
infectious diseases, thus increasing neonatal disorders’ 
share of total DALYs. Among injuries in this age group, 
drowning saw the largest decline in DALYs. The position 
of congenital syphilis among the top ten causes of 
DALYs in children is indicative of health system failure. 
With testing and treatment in the second trimester of 
pregnancy, this cause could be eliminated.23 The main 
reasons for failure are limited access to health services, 
the low use of rapid diagnostic tests, the failure of 
antenatal clinics to screen or treat when a woman is 
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tested positive, and the recent global shortage of 
benzathine penicillin, the treatment of choice.24 Despite 
the large health gains among children younger than 
10 years, considerable burdens still remain in sub-
Saharan Africa. Sustaining the global pace of progress 
will become more challenging as an ever-increasing 
proportion of the global birth cohort is born in sub-
Saharan Africa,25 with the highest rates of burden in 
these age groups. It is encouraging, however, that the 
largest decreases in DALY rates globally have occurred in 
sub-Saharan African countries, such as Ethiopia, Angola, 
Rwanda, and Malawi, although there are others that 
have seen much less progress. 
Among the top ten causes of DALYs in adolescents 
aged 10–24 years, self-harm had the largest decline 
(28·4% [95% UI 18·9–36·3]) over the study period. The 
prevalence of depressive disorders and other mental 
disorders, which are major underlying causes of self-
harm,26 did not change, suggesting that the decline in 
self-harm deaths was largely due to other factors such as 
better access to mental health services, urbanisation, and 
a reduction in access to more lethal means of suicide.27–30 
The increase in DALY rates of neonatal disorders in this 
age group is a downside to the large improvements in 
neonatal survival, causing a greater proportion of the 
surviving babies to have long-term neurological and 
sensory deficits. 
In the 25–49-year age group, HIV/AIDS was the second 
leading cause of DALYs in 2019 despite a drop since 2005, 
when ART became more widely available.31 To be on 
course to end HIV/AIDS as a public health threat 
by 2030, UNAIDS estimates that a substantial increase in 
global funding would be required, whereas high-income 
countries have reduced their funding.32 The prominent 
position of headache disorders in the DALY rankings in 
the 10–24-year and 25–49-year age groups has received 
little attention in global health policy debates. While 
there is no cure for these disorders, there are effective 
symptomatic and preventive treatments available.33 
Ischaemic heart disease, stroke, and diabetes were not 
among the 25 leading causes in the two younger age 
groups, but emerged as major contributors to burden in 
the 25–49-year age group and, more prominently, in the 
older age groups that follow. These diseases share many 
common risk factors and treatment approaches. The 
burden in high-income countries has been rapidly 
declining since the 1980s, but a more recent downturn in 
this decline over the past 5 years has been noted as an 
important explanation for the slowdown in life expectancy 
gains.34 Low-income and middle-income countries still 
have ample opportunity to make greater use of known 
effective intervention strategies (tobacco control, blood 
pressure-lowering and cholesterol-lowering treatments, 
and emergency response and treatment for acute events) 
that have been so effective in high-income countries.35 
However, the rising prevalence of diabetes, linked to the 
almost ubiquitous increase in body-mass index globally,36 
is mitigating the pathway to reducing the burden of 
cardiovascular diseases.37,38 In the 25–49-year age group, 
tuberculosis that is not associated with HIV infection 
ranked among the top ten causes in 2019. There are 
similar worries about sustained global funding of 
tuberculosis control as mentioned for HIV/AIDS, let 
alone having the additional resources and research 
development effort that would be required to reach 
WHO’s goals to reduce the 2015 levels of tuberculosis 
deaths and incidence by 90% and 80%, respectively, by 
the year 2030.39–41 
The prominent rankings of COPD and lung cancer
in the 50–74-year and 75-years-and-older age groups
emphasise the continuing need for tobacco-control
measures and attention to reducing exposure to indoor
and outdoor air pollution. Already, low-income and
middle-income countries account for 62·6% of the
global burden of COPD and lung cancer, and this share
is likely to increase sharply over coming decades due to
ageing populations and less successful tobacco and air
pollution control. The finding that lung cancer DALY
rates are declining in the 50–74-year age group but not in
those aged 75 years and older is probably due to a cohort
effect; this could be encouraging if it reflects a greater
response to tobacco control in younger generations that
will drive further declines in coming years. Chronic
kidney disease is strongly linked to cardiovascular
diseases and diabetes, and shares common risks and
intervention approaches.42 Given its prominent position
in the top ten rankings of DALYs in older age groups and
the costs associated with end-stage kidney disease
treatments, screening and low-cost treatments at earlier
stages of chronic kidney disease should be more widely
implemented.43 Cirrhosis ranked seventh among those
aged 50–74 years in 2019. With low-cost treatments
available to low-income and middle-income countries,
there is an opportunity to eradicate hepatitis C as an
underlying cause—a strategy that Egypt is well on the
way to achieving in coming years.19 Childhood vac­
cinations for hepatitis B will eventually also reduce
cirrhosis (and liver cancer) outcomes, but the full effect
will probably not be apparent for years. Alcohol is the
third modifiable cause of cirrhosis; there is strong
evidence that taxation and regulations can reduce alcohol
use to less harmful levels.44 Age-related hearing loss is a
top ten cause of DALYs in the two older age groups.
While some reduction in burden can be achieved by
control of loud noises during leisure or occupational
activities, most of the burden cannot be prevented
through currently known strategies. For a large propor­
tion of the elderly, hearing aids can relieve some of the
symptoms and associated social isolation. The quality of
hearing aids has improved over the past decade, but low-
cost appliances are not readily available in low-income
and middle-income countries.45 
Alzheimer’s disease and other dementias, and falls are 
two causes that appear in the top ten ranking of DALYs 
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only for those aged 75 years and older. The ability to 
intervene by prevention or treatment for dementia is still 
limited despite a large research and development effort 
to identify drugs, but efforts continue.46 There is good 
evidence that a range of modifiable risks (tobacco, 
physical inactivity, metabolic risks, and hearing loss) 
contribute to the development of dementia,47,48 but little 
evidence of the effectiveness of interventions addressing 
these risk factors.47,49 Falls in the elderly are common and 
linked to psychotropic and cardiovascular medications,50 
cognitive impairment, depression, and general frailty.51,52 
There is evidence for the effectiveness of multifactorial 
interventions combining education, exercise, and home 
safety modification interventions.53 
The trend towards disability as an increasing share of 
overall burden has continued. In 11 countries, more than 
half the burden was from YLDs of NCDs and injuries in 
2019. To some extent, the absence of a discernible trend 
in disability might be an artifact of the poor availability of 
data on severity, and, therefore, an inability to quantify 
the effect of health service interventions that modulate 
severity. The larger issue, however, is that most of the 
focus of global public health has been on life-saving 
interventions directed at the main causes of death.7,54,55 
The large contributors to disability, such as muscu­
loskeletal conditions and mental disorders, are associated 
with few deaths. As disability becomes an increasingly 
large component of disease burden and, as importantly, 
a larger component of health expenditure, a greater 
research development investment is needed to identify 
new, and more effective, intervention strategies.56–58 With 
a rapidly ageing global population, the demands on 
health services to deal with disabling outcomes, which 
increase with age, will require policy makers to anticipate 
these changes. GBD provides key information on the 
changes in types of health services in terms of facilities 
and adequately trained personnel that will be needed. 
The finding that health gains in countries at the lower
end of the SDI scale have, on average, accelerated over the
past decade compared with the two decades before
indicates the potential for low-income countries to make
a real difference by investing in health. Progress, however,
has been uneven. The more recent downturn in reduc­
tions in DALY rates in countries and territories with
higher SDI is striking and near universal, although an
actual reversal into increases of age-standardised DALY
rates has only happened in a small number of countries
in the Caribbean and the USA. Plausible drivers of this
change include obesity, diminishing potential for further
reductions in smoking, and improvements in coverage of
treatments for high blood pressure and cholesterol to
maintain the past declines in cardiovascular mortality.34 
Inequalities in access to preventive and curative services
by lower socioeconomic groups might be a further
obstacle to continued improvements in cardiovascular
mortality.59 The large increase in drug overdose deaths in
the USA and the increasing number of deaths from
violence in Latin American countries, in addition to
the decelerated decline of cardiovascular mortality, are
driving the patterns in these locations. The mix of
universal and more geographically specific influences on
health reinforces the need for regular, detailed reporting
on population health by underlying cause to help decision
makers to identify success stories of disease control, as
well as opportunities to improve and emulate countries
that are performing well. 
Limitations 
The major limitation of the GBD analysis of the burden 
of diseases and injuries is the availability of primary data. 
Where data are not available, the results depend on the 
out-of-sample predictive validity of the modelling efforts. 
While improvements to data processing and modelling 
can lead to incremental improvements in the accuracy of 
our estimates, fundamental improvements require more 
and better primary data collection. Even when data are 
available, they might not have been obtained using 
the preferred case definition or measurement method. 
The more explicit identification of the preferred and 
alternative measurement method for each outcome, and 
the bias mapping from alternative to reference method 
undertaken as part of GBD 2019, have led to greater 
stability in data adjustments. These improvements will 
also aid in identifying priorities for data collection and 
in determining preferred case definitions and study 
methods. Moving to use of standard locations for 
estimating fixed effects in the models will aid in cycle-to­
cycle stability of models. Through the use of standard 
locations, the addition of more subnational units in a 
given GBD cycle should not shift the regression model 
predictions as much as they previously would have. 
Nevertheless, collinearity between covariates in some of 
these models might contribute to some instability in 
fixed effects between cycles. Future work on ensemble 
models might help to solve the collinearity problem. Of 
note, because the cause of death models developed using 
CODEm are an ensemble of all high-performing possible 
models, they avoid the instability due to collinearity. 
Although our statistical modelling is designed to capture 
uncertainty from stochastic variation in input data, age 
and sex splitting of data, corrections for alternative case 
definitions or uninformative cause of death codes, other 
data manipulations, and model choice, it remains a 
challenge to fully represent the UIs around estimates, 
particularly in locations with sparse or absent data. This 
will remain a major focus of GBD by tapping into existing 
knowledge in other estimation fields as well as our own 
development of methods. 
The shift to adjusting dementia deaths to reflect
only those with end-stage disease is conceptually more
appealing than the past crude adjustment for the large
variation in coding practices. We will, however, need to
replicate the methods of determining the share of excess
mortality in people with dementia who are in the last
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stages of the disease and for whom an assignment of
dementia as the underlying cause of death is therefore
justified. A greater focus in future rounds of GBD will
need to be directed to identifying data of treatment effects
on severity distributions of the large contributors to
YLDs, such as mental, neurological, and musculoskeletal
disorders, for which we currently do not distinguish
geographical variation in severity. This is of particular
importance as these conditions represent an increasing
share of total burden. Our effort to improve the consis­
tency between mortality rates, prevalence, and incidence
for selected conditions by providing more explicit
guidance on excess mortality rates in DisMod-MR has
revealed that more attention will be required in future
rounds of GBD. After imposing a pattern of excess
mortality that follows an expected pattern of lower rates
in countries with better health systems, the models might
predict prevalence or incidence estimates that are far
removed from observed data. The challenge is then to
identify whether the inconsistency is due to error in the
cause of death estimates, the non-fatal data sources, or a
combination of the two. In addition to these general
limitations, there are many limitations for each specific
modelling exercise reported in this study. Appendix 1
(sections 3.4 and 4.12) provides more insight into some of
these issues. 
Future directions 
Several method improvements signalled in previous
GBD publications have not yet been implemented but
remain a priority. For instance, DisMod-AT, a new version
of our main non-fatal modelling tool that simultaneously
solves for patterns over age and time, is still undergoing
testing before it can be implemented in GBD. Methods to
make dependent comorbidity corrections computationally
feasible, and imposing greater variation in severity
distributions based on access to and quality of health
care, are also still under development. More generally,
imposing GBD principles and methods to the estimation
of access to health interventions and the effectiveness
thereof, and being able to link those estimates with our
future health scenario platform25 is a direction we are
keen to take. Developing this comprehensively is a large
endeavour that will take many years to complete. As this
would greatly add value to the policy relevance of GBD,
we will also aim to develop less comprehensive methods
that will nevertheless allow us to respond to policy makers
seeking information on major policy decisions in a more
timely fashion. 
Conclusion 
Taking into account population growth and shifts in age 
structure, health continues to improve at the global level. 
The absolute burden of disease and its associated impact 
on health systems, however, remain resolutely constant. 
Some diseases, such as diabetes, are increasing in 
burden, and more general all-cause DALY stagnation in 
some high SDI countries points out that further gains 
are not inevitable. Close monitoring of health trends and 
careful policy evaluation of the options to counteract 
adverse trends is required. Leading causes of DALYs, as 
well as solutions, differ substantially across age groups, 
highlighting the need to formulate policy for different 
phases of the life course. 
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